Chromone derivatives as matrix metalloproteinase inhibitors
US6908917B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Aug 5, 2003 |
| Grant date | Jun 21, 2005 |
| Priority date | — |
| Expiry date | Aug 25, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D265/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof,wherein R1, Q, Y2, Y3, Y4, U5, U6, U8, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonar…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.